5. Commitments and Contingencies : Royalties  In January 2016, the Company signed a license agreement with The Royal Institution for the Advancement of Learning/McGill University in Canada on the Companys potential products. This agreement requires, for each of the Companys potential products, a 3% payment of annual net revenues, with a minimum royalty of CAD $5,000 each, per year starting on the date of commercialization of the first product developed using the intellectual property covered by the license agreement. The Company must pay milestone payments for the androgen replacement treatment as follows: ? CAD $5,000 on the issuance of the first US patent that accrued US$3,750 in the first quarter of 2019 ? CAD $25,000 on the filing of an investigational new drug application or regulatory filing ? CAD $50,000 on the initiation of the first Phase II clinical study ? CAD $100,000 on the initiation of the first Phase III clinical study ? CAD $300,000 on receipt of regulatory approval The Company must also pay milestone payments as follows for the out of body test to identify Alzheimers disease as follows: ? CAD $5,000 on the issuance of the first US patent ? CAD $50,000 on the filing of a 510(k) or PMA application ? CAD $200,000 on receipt of regulatory approval In addition, the Company issued 5% of the total number of issued and outstanding shares in the Companys Series A financing to the same institution, or 1,652,632 shares in March 2016. This agreement, payable in Canadian dollars, exposes the Company to foreign exchange transaction gains and losses. In August 2016, the Company issued an additional 300,000 shares of the Companys common stock to McGill in lieu of the pre-existing anti-dilution provision. As McGill owns more than 5% of the Companys outstanding common stock, it is considered a related party. Research Agreement  In January 2016 the Company signed a Research Agreement with The Research Institute of the McGill University Health Centre (RIMUHC) in Canada for research activities on the Companys potential products. The agreement covers a period of one year and required the Company to pay a total of $130,000. The Agreement was amended in March 2017 to extend the term for one year and required the payment of an additional $130,000 over that period. The Company paid these installment payments in July and October 2017 leaving no balance due. The Company agreed in June 2018 to an additional payment of $65,000 to continue research and development activities at RIMUHC and signed an extension of the agreement in January 2019 requiring an additional payment of $35,000, which was paid in April 2019. Scientific Advisory Board  In September 2018 we executed agreements with four new members of our Scientific Advisory Board (SAB) through which each new member received a warrant to purchase up to 35,000 shares of our common stock at an exercise price of $0.01 per share for a period of one year. In addition, each new SAB member will be paid an annual fee of $25,000, paid quarterly, commencing with the first scheduled SAB meeting that occurred November 2018. These agreements may be renewed annually, under the same terms and conditions, should each members appointment to the SAB be continued. In March 2019, 35,000 of these warrants were exercised by a member of our SAB. During the nine-month period ended September 30, 2019, we incurred $75,000 in expense related to these agreements. Consulting Agreement  In September 2019 we executed a consulting agreement through which an independent third party received a warrant to purchase 500,000 shares of common stock of the Company, exercisable at $0.01 per share for a period of up to ten years. The consultant is also is eligible to receive a warrant to purchase up to 500,000 shares of common stock of the Company, exercisable at $0.01 per share for a period of up to ten years, upon submission of an IND to the Food and Drug Administration. The term of the Agreement is for a period of twelve months and may be terminated by either party with thirty days written notice. The consultant is also eligible to receive piggyback registration rights should the Corporation file a future registration statement with the U.S. Securities and Exchange Commission.